# A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

> **NCT04555824** · PHASE1 · COMPLETED · sponsor: **Beijing Northland Biotech. Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Recombinant Human Thymosin β4
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04555824
- **Lead sponsor:** Beijing Northland Biotech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-17
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-06-20
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555824, "A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04555824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*